Molecular and Cellular Basis of Disease (MCBD)

1. Molecular and Cellular Basis of Disease (MCBD)

2. Cell Injury

3. + Stress Normal cell Adapted Cell - Stress +Stress Injury - Stress Reversibly injured cell Apoptosis Irreversibly Injured cell Dead cell Necrosis Overview

7. Normal cell + Stress Adapted Cell - Stress Cellular adaptation

8. Normal cell +Stress Adapted Cell - Stress Stress = ? Increased/decreased workload *skeletal muscle and body building * cardiac muscle and hypertension * skeletal muscle disuse (limb immobilization) Increased/decreased stimulation * estrogenic stimulation of uterus in pregnancy * estrogen/prolactin stimulation of breast (lactation) * denervation of muscle

9. Adapted Cell Cellular adaptations to stress 1. Hyperplasia (more cells) 2. Hypertrophy (bigger cells) 3. Atrophy (smaller cells) 4. Metaplasia (different type of cells)

10. 1. Physiologic * Hormonal (breast/uterus in pregnancy) * Compensatory (liver after partial hepatectomy) 2. Pathologic Excessive hormone/GF stimulation of target tissue * Endometrial hyperplasia (x’s estrogen) * Benign prostatic hyperplasia (x’s androgens) * Connective tissue cells in wound healing 1. Hyperplasia (more cells)

11. Thyroid hyperplasia

12. Cell proliferation via increased production of TRANSCRIPTION FACTORS due to *Increased production of GF * Increased levels of GF receptors * Activation of intracellular signaling Results in larger organ Hyperplasia (Mechanism)

13. Adapted Cell 2. Hypertrophy(larger cells) * Not due to swelling * Increased synthesis of structural components * Results in larger organ * May occur with hyperplasia

14. Hypertrophy Comments * Often involves switch from adult to fetal/neonatal formsi.e. a-myosin heavy chain  b-myosin heavy chain * Limited (can only increase so much)

15. Hypertrophy (Heart)

16. Hypertrophy of uterus

17. Normal Hypertrophied Cardiac smooth muscle hypertrophy

18. Hypertrophy(Mechanisms) • Increased synthesis of structural proteins via • Transcription factors (i. e. c-fos and c-jun) • Growth factors (TGF-b, IGF-1, FGF) • Vasoactive agents (endothelien-1, AII)

19. Figure 1-4 Changes in the expression of selected genes and proteins during myocardial hypertrophy.

20. 3. Atrophy(smaller cells) • 1. Physiologic • During development: i.e. notochord; thyroglossal duct 2. Pathologic(local or generalized) via * disuse * Loss of endocrine stimulation * denervation * Aging * ischemia * Pressure * Nutrition

22. Normal Atrophied Brain atrophy

23. Muscle fiber atrophy. The number of cells is the same as before the atrophy occurred, but the size of some fibers is reduced. This is a response to injury by "downsizing" to conserve the cell. In this case, innervation of the small fibers in the center was lost. This is a trichrome stain.

24. Atrophy (Mechanism) Reduction in structural components Decreased number of mito, myofilaments, ER via proteolysis (lysosomal proteases; ubiquitin-proteosome system) Increase in number of autophagic vacuoles Residual bodies (i.e. lipofuscin  brown atrophy) NB: diminished function but not dead

25. 4. Metaplasia **One adult cell type replaces another** Reversible Columnar to squamous epithelium (most common epithelial type of metaplasia) Chronic irritation i.e.(in trachea and bronchi of smokers) Vit A deficiency squamous metaplasia in respiratory epithelium May be some loss of function May predispose to maligancy

26. Photomicrograph of the trachea from a smoker. Note that the columnar ciliated epithelium has been replaced by squamous epithelium.

27. Photomicrograph of the junction of normal epithelium (1) with hyperplastic transitional epithelium (2).

28. Metaplasia(Mechanism) Reprogramming 1. of stem cells present in normal tissues 2. of undifferentiated mesenchymal cells in connective tissue Mediated by signals from cytokines, GF or ECM Leading to induction of specific transcription factors